Seeking Alpha


Send Message
View as an RSS Feed
View snortinnorton10's Comments BY TICKER:
Latest  |  Highest rated
  • MannKind: Do Insider Sales Transactions Indicate This Is A Fool's Rally? [View article]
    Wow - zero mention that they were planned sales, not impulsive based on a surging stock price. I award you zero points for objectivity, quite deceitful actually.

    These sales were planned prior to a 3 month delay - the sellers had anticipated that we would have been post-approval and post-partner at this point.

    Worthless scare tactics.
    Jun 12, 2014. 10:11 AM | 38 Likes Like |Link to Comment
  • 4 Reasons Tonix Could Be A Multi-Bagger [View article]

    Thanks as always for the objective 360 degree analysis. Curious how you would currently rank your picks: MNKD, IMUC, HYGS and TNXP? Have you scaled out of any and where are you adding?

    Knowing is half the battle :) - Thanks again.
    Dec 3, 2013. 03:21 PM | Likes Like |Link to Comment
  • Halozyme Has Safest Ultrafast Insulin [View instapost]
    Nice reference:

    "The relevance of these findings may be in that inhaled formulations of insulin that were once promising, approved strategies for treatment of diabetes mellitus in US and Europe [51, 52] have been withdrawn due to persistent reports of respiratory problems, including cough."

    51. L. M. Hunt, M. A. Valenzuela, and J. A. Pugh, “NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance,” Diabetes Care, vol. 20, no. 3, pp. 292–298, 1997.: This study examines NIDDM patients' attitudes toward insulin injections, the basis of these attitudes and how they may affect patients' willingness to take insulin. RESEARCH DESIGN AND METHODS - Forty-four low- income Mexican American NIDDM patients were interviewed using open-ended in- depth interviewing techniques.

    So your thesis is based on an open-ended interview with 44 low income mexican american patients pre-afrezza in 1997? Solid.
    Dec 1, 2013. 01:46 PM | 1 Like Like |Link to Comment
  • Log Up And Line On To Netflix [View instapost]
    G.I. Joe!
    Oct 25, 2013. 02:36 PM | Likes Like |Link to Comment
  • 6 Reasons ImmunoCellular Therapeutics Is One Of The Best Risk Vs. Rewards In The Market [View article]
    Any insight into the timing of PII results? I've heard multiple theories. Thanks as always for the unparalleled and objective analysis!
    Aug 7, 2013. 12:54 PM | Likes Like |Link to Comment
  • Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market [View article]
    "Normalcy bias?"
    So users of the rotary phone should never have adopted touchtone? Postal customers should never have used email?
    Jun 18, 2013. 12:43 PM | 3 Likes Like |Link to Comment
  • MannKind's Afrezza Likely To Easily Gain Approval [View article]

    Put all of your due diligence against Joe's and it's clear who has a clear, objective comprehension of the Mannkind story.

    I really wish you had said TheStreet has relationships with parties that would benefit if MNKD trades lower. That would at least make you 'motivated'. Instead you are just either stuck in a debate you don't have the stones to admit you lost, or you are really just that slow. Your subjective pieces that leave out most of the critical details that make a complete analysis leave us no other conclusion. Kind of embarrassing for a 'Journalist' isn't it?? Take the time to read Joe's lengthy and COMPLETE article. You might learn something.
    Apr 17, 2013. 10:43 PM | 1 Like Like |Link to Comment
  • MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial [View article]
    MAPP - inhaled and recently approved.
    Apr 12, 2013. 02:18 PM | 2 Likes Like |Link to Comment
  • MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial [View article]
    You are seriously opening yourself up to a DD shredding by allowing comments... See Joe Springer for what DD looks like. Good Luck!
    Apr 12, 2013. 04:16 AM | 4 Likes Like |Link to Comment
  • MAP's Levadex Ready For FDA Approval [View article]
    Wendy, please explain what you are referring to re: MNKD's "pulmonary side effects". Thanks.
    Feb 3, 2013. 11:29 AM | 1 Like Like |Link to Comment
  • Tempur-Pedic Is Severely Undervalued [View article]
    What about recent growth?? SCSS is the winner..
    Sep 19, 2012. 01:30 PM | 1 Like Like |Link to Comment